Evogene (NASDAQ:EVGN) Share Price Passes Below 200 Day Moving Average – What’s Next?

Evogene Ltd. (NASDAQ:EVGN) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.87 and traded as low as $1.36. Evogene shares last traded at $1.38, with a volume of 35,602 shares trading hands.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EVGN. StockNews.com began coverage on shares of Evogene in a research note on Wednesday. They issued a “sell” rating for the company. Alliance Global Partners reissued a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Trading Down 1.1 %

The business’s 50-day moving average price is $1.50 and its 200-day moving average price is $1.87. The stock has a market cap of $7.38 million, a PE ratio of -0.31 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The firm had revenue of $1.61 million during the quarter, compared to analyst estimates of $3.63 million. During the same quarter in the prior year, the business posted ($1.30) EPS.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene at the end of the most recent reporting period. 10.40% of the stock is currently owned by institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.